SARS-CoV-2 ORF7a-10 (69-86)
DGVKHVYQLRARSVSPKL-acid
Description
Application Data
Description
-
The SARS-CoV-2 ORF7a-10 protein sequence DGVKHVYQLRARSVSPKL (69-86) has been identified as an epitope for anti-viral targeting.
Application Data
-
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001840 Molecular Weight 2052.2 Sequence (one letter code) DGVKHVYQLRARSVSPKL-acid
Sequence (three letter code) H-Asp-Gly-Val-Lys-His-Val-Tyr-Gln-Leu-Arg-Ala-Arg-Ser-Val-Ser-Pro-Lys-Leu-OH
Purity >95% Storage -20°C References Arshad et al., (2023). SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. PNAS, 120(1): e2208525120. DOI: 10.1073/pnas.2208525120.
Manufactured in: United Kingdom ORF7a is an accessory protein that is key to SARS-CoV-2 evading the immune system. ORF7a acts on the secretory pathway to lower surface MHC-I expression by specifically interacting with the MHC-I heavy chain and delaying its export from the endoplasmic reticulum. These factors make the ORF6 protein a viable target for developing new antiviral drugs. In addition, the identification of epitopes within the ORF7a-10 protein sequence can help design more effective SARS-CoV-2 vaccines.
Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. ORF7a-10 protein (69-86) is an epitope candidate with various predicted HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.